Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells

Blood

Volumn 109, Issue 9, 2007, Pages 3929-3935

  Tissing, Wim J E ^a,b   Den Boer, Monique L ^a   Meijerink, Jules P P ^a   Menezes, Renee X ^a,c   Swagemakers, Sigrid ^d   Van Der Spek, Peter J ^d   Sallan, Stephen E ^e   Armstrong, Scott A ^e   Pieters, Rob ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PREDNISOLONE; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE;

EID: 34247490700     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-11-056366     Document Type: Article

References (53)

1. Lauten M, Stanulla M, Zimmermann M, Welte K, Riehm H, Schrappe M. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr. 2001;213:169-174.
2. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood. 1998;92:259-266.
3. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood. 1997;89:2959-2965.
4. Tsai SY, Carlstedt-Duke J, Weigel NL, et al. Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell. 1988;55:361-369.
5. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev. 2003;24:488-522.
6. Tissing WJ, Meijerink JP, den Boer ML, Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia. 2003;17:17-25.
7. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004;11(suppl 1):S45-S55.
8. Tonko M, Ausserlechner MJ, Bernhard D, Helmberg A, Kofler R. Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoidinduced apoptosis. FASEB J. 2001;15:693-699.
9. Obexer P, Certa U, Kofler R, Helmberg A. Expression profiling of glucocorticoid-treated T-ALL cell lines: rapid repression of multiple genes involved in RNA-, protein- and nucleotide synthesis. Oncogene. 2001;20:4324-4336.
10. Planey SL, Abrams MT, Robertson NM, Litwack G. Role of apical caspases and glucocorticoidregulated genes in glucocorticoid-induced apoptosis of pre-B leukemic cells. Cancer Res. 2003;63:172-178.
11. Yoshida NL, Miyashita T, UM, et al. Analysis of gene expression patterns during glucocorticoid-induced apoptosis using oligonucleotide arrays. Biochem Biophys Res Commun. 2002;293:1254-1261.
12. Wang Z, Malone MH, He H, McColl KS, Distelhorst CW. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem. 2003;278:23861-23867.
13. Schmidt S, Rainer J, Riml S, et al. Identification of glucocorticoid-responsive genes in children with acute lymphoblastic leukemia. Blood. 2006;107:2061-2069.
14. Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL generearranged infant acute lymphoblastic leukemia. Blood. 2003;101:1270-1276.
15. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41-47.
16. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-542.
17. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantifi-cation of differential expression. Bioinformatics. 2002;18(suppl 1):S96-S104.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B. 1995;57:289-300.
19. R development core team. R: a language and environment for statistical computing. Vienna, Austria: R foundation for statistical computing, 2005. http://www.r-project.org. Accessed October 11, 2004.
20. Cole SW, Yan W, Galic Z, Arevalo J, Zack JA. Expression-based monitoring of transcription factor activity: the TELiS database. Bioinformatics. 2005;21:803-810.
21. Cole S, UC Regents. TELiS: the transcription element listening system. http://www.telis.ucla.edu/index.htm. Accessed March 23, 2005.
22. Gene Ontology Consortium. Gene ontology database. http://geneontology. org. Accessed October 30, 2004.
23. Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer LM. A genome-wide view of the in vitro response to L-asparaginase in acute lymphoblastic leukemia. Cancer Re. 2005;65:291-299.
24. Vermeer H, Hendriks-Stegeman BI, van der Burg B, van Buul-Offers SC, Jansen M. Glucocorticoidinduced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J Clin Endocrinol Metab. 2003;88:277-284.
25. U M, Shen L, Oshida T, Miyauchi J, Yamada M, Miyashita T. Identification of novel direct transcriptional targets of glucocorticoid receptor. Leukemia. 2004;18:1850-1856.
26. Han SH, Jeon JH, Ju HR, et al. VDUP1 upregulated by TGF-beta1 and 1,25-dihydroxyvitamin D3 inhibits tumor cell growth by blocking cellcycle progression. Oncogene. 2003;22:4035-4046.
27. Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res. 2002;90:1259-1266.
28. Junn E, Han SH, Im JY, et al. Vitamin D3 up-regulated protein 1 mediates oxidative strss via suppressing the thioredoxin function. J. Immunol. 2000;164:6287-6295.
29. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem. 2004;279:30369-30374.
30. Wang Z, Rong YP, Malone MH, Davis MC, Zhong F, Distelhorst CW. Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis. Oncogene. 2006;25:1910-1913.
31. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101:4667-4679.
32. Ravandi F, Talpaz M, Kantarjian H, Estrov Z. Cellular signaling pathways: new targets in leukaemia therapy. Br J Haematol. 2002;116:57-77.
33. Miller AL, Webb MS, Copik AJ, et al. p38 MAP kinase is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol. 2005;19:1569-1583.
34. Delfino DV, Agostini M, Spinicelli S, Vito P, Riccardi C. Decrease of Bcl-xL and augmentation of thymoctye apoptosis in GILZ overexpressing transgenic mice. Blood. 2004;104:4134-4141.
35. Abrahams MT, Robertson NM, Litwack G, Wickstrom E. Evaluation of glucocorticoid sensitivity in 697 pre-B acute lymphoblastic leukemia cells after overexpression or silencing of MAP kinase phosphatase-1. J Cancer Res Clin Oncol. 2005;131:347-354.
36. Mikosz CA, Brickley DR, Sharkey MS, MoranTW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem. 2001;276:16649-16654.
37. Ayroldi E, Migliorati G, Bruscoli S, et al. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. Blood. 2001;98:743-753.
38. Chen F. Endogenous inhibitors of nuclear factorkappaB, an opportunity for cancer control. Cancer Res. 2004;64:8135-8138.
39. Medh RD, Saeed MF, Johnson BH, Thompson EB. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression. Cancer Res. 1998;58:3684-3693.
40. Medh RD, Webb MS, Miller AL, et al. Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003;81:543-555.
41. Hubler TR, Scammell JG. Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids. Cell Stress Chaperones. 2004;9:243-252.
42. Asselin-Labat ML, David M, Biola-Vidamment A, et al. GILZ, a new target for the transcription factor FoxO3, protects T lymphocytes from interleukin-2 withdrawal-induced apoptosis. Blood. 2004;104:215-223.
43. Naray-Fejes-Toth A, Fejes-Toth G, Volk KA, Stokes JB. SGK is a primary glucocorticoid-induced gene in the human. J Steroid Biochem Mol Biol. 2000;75:51-56.
44. Leong ML, Maiyar AC, Kim B, O'Keeffe BA, Firestone GL. Expression of the serum- and glucocorticoid-inducible protein kinase, SGK, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem. 2003;278:5871-5882.
45. Webb MS, Miller AL, Johnson BH, et al. Gene networks in glucocorticoid-evoked apoptosis of leukemic cells. J Steroid Biochem Mol Biol. 2003;85:183-193.
46. Jeon JW, Lee SJ, Kim JB, et al. Cellular proliferative effect of dexamethasone in immortalized trabecular meshwork cell (TM5) line. Yonsei Med J. 2003;44:299-306.
47. Kasinath BS, Singh AK, Kanwar YS, Lewis EJ. Dexamethasone increases heparan sulfate proteoglycan core protein content of glomerular epithelial cells. J Lab Clin Med. 1990;115:196-202.
48. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002;365:561-575.
49. Taylor WM, Goldrick RB, Ishikawa T. Glycerokinase in rat and human adipose tissue: response to hormonal and dietary stimuli. Horm Metab Res. 1979;11:280284.
50. Hu X, Li WP, Meng C, Ivashkiv LB. Inhibition of IFN-gamma signaling by glucocorticoids. J Immunol. 2003;170:4833-4839.
51. Leal MA, Aller P, Calle C. Effect of dexamethasone on insulin receptor mRNAlevels, RNAstability and isotype RNApattern in U-937 human promonocytic cells. J Endocrinol Invest. 1996;19:530-534.
52. Celander M,Weisbrod R, Stegeman JJ. Glucocorticoid potentiation of cytochrome p4501A1 induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin in porcine and human endothelial cells in culture. Biochem Biophys Res Commun. 1997;232:749-753.
53. Hermoso MA, Matsuguchi T, Smoak K, Cidlowski JA. Glucocorticoids and tumor necrosis factor alpha cooperatively regulate toll-like receptor 2 gene expression. Mol Cell Biol. 2004;24:4743-4756.